RxDoctor Payments Data

Arash Vahdat, MD

Interventional Cardiology · Tarzana, CANPI 1225134232

Payments from drug & device makers

$87,603in general payments, 2019–2025

Across 699 payments — averaging $125.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$47K
  • Abbott$30K
  • Novartis$1K
  • Johnson & Johnson$1K
  • Pfizer$837
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$816
  • plus $7K from 33 others

What the payments were for

  • Consulting fees$23,60127%
  • Speaking & faculty fees$44,20250%
  • Travel & lodging$4,1155%
  • Food & beverage$15,57718%
  • Education$1070%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,603 in reported general payments places this provider in the 80th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$1,110,157
Medicare patients
1,709
Services billed
12,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban446$376,657
Repatha SureclickEvolocumab319$195,511
EntrestoSacubitril/Valsartan155$149,251
FarxigaDapagliflozin Propanediol158$145,253
XareltoRivaroxaban147$116,911
VascepaIcosapent Ethyl134$61,492
JardianceEmpagliflozin73$58,663
MultaqDronedarone Hcl51$50,411
BrilintaTicagrelor75$48,133
VerquvoVericiguat35$32,542
OzempicSemaglutide25$23,669
Praluent PenAlirocumab42$21,266
DapagliflozinDapagliflozin Propanediol33$18,511
CorlanorIvabradine Hcl21$15,548
Icosapent Ethyl80$14,733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$837$376,657446 claims
AstraZenecaFarxiga, Brilinta$700$193,386233 claims
NovartisEntresto$1,358$149,251155 claims
Johnson & JohnsonXarelto$1,128$116,911147 claims
Boehringer IngelheimJardiance$345$58,66373 claims
Sanofi-aventis U.S. LLCMultaq$658$50,41151 claims
MerckVerquvo$125$32,54235 claims
Novo NordiskOzempic$92$23,66925 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$446$20,12136 claims
AmgenCorlanor$46,706$15,54821 claims
Lexicon Pharmaceuticals, Inc.Inpefa$107$8,72215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Tarzana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →